Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) secures regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia
- The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the country, targeting a population of more than 33 million
- SPL’s registrations for the spray now spans more than 35 countries, including Europe and the UK
- Meanwhile, Starpharma has been conducting a post-market clinical study of VIRALEZE in the UK in patients with COVID-19 to examine the spray’s ability to reduce viral load over a seven-day period
- Starpharma is up 2.56 per cent, trading at 40 cents at 10:25 am AEST
Starpharma (SPL) has secured regulatory approval for its antiviral nasal spray in Malaysia.
The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the country, targeting a population of over 33 million.
SPL’s registrations for the spray now spans more than 35 countries, including Europe and the UK, and is available in pharmacies, retail outlets and online. Discussions are underway with commercial partners in other countries.
VIRALEZE works by physically trapping and blocking cold and respiratory viruses in the nasal cavity, including coronaviruses, influenza, rhinoviruses and respiratory syncytial viruses (RSV).
CEO of Starpharma Dr Jackie Fairley said the company is pleased to have added another Asian market to the growing list of countries where VIRALEZE nasal spray is registered.
“VIRALEZE will be available immediately to consumers in Malaysia through an online webstore and Starpharma also plans to make the product available locally through retail outlets, including pharmacies, as it is in Vietnam, Hong Kong, Macau, UK, and Italy,” Dr Fairley said.
Meanwhile, Starpharma is also conducting a post-market clinical study of VIRALEZE in the UK in patients with COVID-19 to examine the antiviral activity and ability of the spray to reduce viral load over a seven-day period.
SPL shares were up 2.56 per cent, trading at 40 cents at 10:25 am AEST.
